Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §102 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 50.0% | +45.2% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.5% |
| MIANO, JOSEPH PAUL | 1 | 37.9% | +63.3% |
| VARADARAJ, ARCHANA | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17289848 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | VARADARAJ, ARCHANA | 77d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 56d overdue |
| 17619108 | HETEROGENEOUS STEM CELL POPULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | MIANO, JOSEPH PAUL | 36d overdue |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 33d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1618 | 1 |
| 1631 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §103 | Non-Final OA | 33d | Pending | May 25, 2023 |
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 1618 | §103 | Non-Final OA | 56d overdue | Pending | Jan 17, 2022 |
| 17619108 | HETEROGENEOUS STEM CELL POPULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | MIANO, JOSEPH PAUL | 1631 | §102 | Final Rejection | 36d overdue | Pending | Dec 14, 2021 |
| 17289848 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | VARADARAJ, ARCHANA | 1658 | §102 | Non-Final OA | 77d overdue | Pending | Nov 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial